Bundamedik Tbk PT BMHS.JK · IDR

Health Care · IDX · 🇮🇩 Indonesia

Compare

184

-3.16%

Close of 9 Nov 2026, in IDR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in IDR, from our data supplier.

FY2025

Revenue

IDR 1.61trn

FY2018FY2025

Net income

IDR 12.42bn

FY2018FY2025

Free cash flow

IDR 31.72bn

FY2018FY2025

Shareholders' equity

IDR 1.95trn

FY2018FY2025

Income statement

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	IDR 1.61trn	IDR 1.55trn	IDR 1.49trn	IDR 1.66trn	IDR 1.71trn	IDR 1.15trn	IDR 964.89bn	IDR 852.23bn
Gross profit	IDR 623.09bn	IDR 707.14bn	IDR 582.26bn	IDR 764.55bn	IDR 823.52bn	IDR 493.15bn	IDR 457.12bn	IDR 397.84bn
Operating income	IDR 115.29bn	IDR 87.95bn	IDR 87.71bn	IDR 216.83bn	IDR 416.19bn	IDR 188.68bn	IDR 103.83bn	IDR 77.71bn
Net income	IDR 12.42bn	IDR 11.94bn	IDR 7.46bn	IDR 128.93bn	IDR 315.36bn	IDR 118.46bn	IDR 31.32bn	IDR 5.13bn
Diluted earnings per share	1.44	1.39	0.87	14.99	36.66	13.77	3.64	0.60

Balance sheet

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total assets	IDR 4.02trn	IDR 3.45trn	IDR 3.08trn	IDR 2.94trn	IDR 2.69trn	IDR 2.16trn	IDR 1.40trn	IDR 1.24trn
Cash and short-term investments	IDR 833.10bn	IDR 299.12bn	IDR 627.82bn	IDR 599.20bn	IDR 797.88bn	IDR 619.38bn	IDR 90.66bn	IDR 98.88bn
Total liabilities	IDR 1.62trn	IDR 1.30trn	IDR 1.28trn	IDR 1.13trn	IDR 1.00trn	IDR 1.11trn	IDR 735.16bn	IDR 708.92bn
Debt	IDR 1.36trn	IDR 1.16trn	IDR 1.12trn	IDR 931.42bn	IDR 669.68bn	IDR 812.15bn	IDR 518.10bn	IDR 533.66bn
Shareholders' equity	IDR 1.95trn	IDR 1.71trn	IDR 1.59trn	IDR 1.60trn	IDR 1.56trn	IDR 995.24bn	IDR 618.58bn	IDR 494.78bn
Shares outstanding	8,603m	8,603m	8,603m	8,603m	8,603m	8,603m	8,603m	8,603m

Cash flow

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Cash from operations	IDR 250.62bn	IDR 33.98bn	IDR 51.44bn	IDR 237.47bn	IDR 349.44bn	IDR 190.36bn	IDR 89.72bn	IDR 43.79bn
Capital spending	−IDR 218.91bn	−IDR 236.03bn	−IDR 209.35bn	−IDR 301.73bn	−IDR 228.08bn	−IDR 49.61bn	−IDR 72.50bn	−IDR 156.54bn
Free cash flow	IDR 31.72bn	−IDR 202.05bn	−IDR 157.91bn	−IDR 64.26bn	IDR 121.36bn	IDR 140.75bn	IDR 17.21bn	−IDR 112.75bn
Dividends paid	−IDR 16.40bn	−IDR 63.93bn	−IDR 22.79bn	−IDR 140.28bn	−IDR 40.85bn	−IDR 10.54bn	−IDR 14.64bn	−IDR 16.35bn

Latest quarters

By quarter end

	Jun 2026	Mar 2026	Dec 2025	Sept 2025	Jun 2025	Mar 2025	Dec 2024	Sept 2024
Revenue	IDR 396.45bn	IDR 371.09bn	IDR 459.45bn	IDR 397.09bn	IDR 378.77bn	IDR 379.03bn	IDR 397.73bn	IDR 372.47bn
Gross profit	IDR 183.19bn	IDR 142.62bn	IDR 184.50bn	IDR 160.08bn	IDR 173.73bn	IDR 170.63bn	IDR 161.93bn	IDR 140.74bn
Operating income	IDR 18.25bn	IDR 16.25bn	IDR 44.98bn	IDR 33.18bn	IDR 16.41bn	IDR 20.96bn	IDR 20.66bn	IDR 16.95bn
Net income	−IDR 9.67bn	IDR 65.7m	IDR 170.3m	IDR 8.35bn	IDR 630.3m	IDR 3.27bn	IDR 148.5m	IDR 831.5m
Diluted earnings per share	-1.12	0.01	0.02	0.97	0.07	0.38	0.02	0.10
Cash from operations	IDR 3.58bn	IDR 273.0m	IDR 199.64bn	IDR 16.03bn	IDR 4.73bn	IDR 30.21bn	−IDR 627.0m	IDR 10.98bn
Capital spending	−IDR 112.88bn	−IDR 39.05bn	−IDR 116.26bn	−IDR 23.31bn	−IDR 7.95bn	−IDR 71.38bn	−IDR 34.76bn	−IDR 50.20bn
Free cash flow	−IDR 109.31bn	−IDR 38.77bn	IDR 83.38bn	−IDR 7.28bn	−IDR 3.22bn	−IDR 41.17bn	−IDR 35.38bn	−IDR 39.22bn
Total assets	IDR 4.13trn	IDR 4.04trn	IDR 4.02trn	IDR 3.64trn	IDR 3.53trn	IDR 3.49trn	IDR 3.45trn	IDR 3.77trn
Cash and short-term investments	IDR 237.22bn	IDR 840.08bn	IDR 833.10bn	IDR 817.23bn	IDR 156.29bn	IDR 171.94bn	IDR 299.12bn	IDR 422.14bn
Debt	IDR 1.40trn	IDR 1.30trn	IDR 1.38trn	IDR 1.32trn	IDR 1.23trn	IDR 1.19trn	IDR 1.16trn	IDR 1.49trn
Shareholders' equity	IDR 1.94trn	IDR 1.95trn	IDR 1.95trn	IDR 1.72trn	IDR 1.71trn	IDR 1.72trn	IDR 1.71trn	IDR 1.60trn

Financial ratios

Data as of 29 Aug 2026

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	38.6%	45.5%	39.1%	46.1%	48.1%	43.0%
Operating margin	7.1%	5.7%	5.9%	13.1%	24.3%	16.4%
Net margin	0.8%	0.8%	0.5%	7.8%	18.4%	10.3%
Return on equity	0.6%	0.7%	0.5%	8.1%	20.2%	11.9%
Return on assets	0.3%	0.3%	0.2%	4.4%	11.7%	5.5%
Free cash flow yield	28.1%	16.2%	15.6%	32.3%	34.6%	14.4%
Revenue growth	3.8%	4.5%	-10.3%	-3.0%	49.0%	19.0%
Earnings growth	4.0%	60.1%	-94.2%	-59.1%	166.2%	278.3%
Current ratio	1.62x	1.92x	1.53x	1.38x	1.39x	1.19x
Debt to equity	0.63x	0.65x	0.66x	0.55x	0.41x	0.81x
Equity ratio	48.5%	49.7%	51.6%	54.3%	58.0%	46.0%
Interest coverage	1.71x	1.29x	1.52x	4.60x	14.86x	3.55x
Buybacks as a share of market value	0.0%	0.0%	0.0%	0.0%	-0.0%	—

Growth per year

Compound annual rate

	3 years	5 years	10 years
Revenue	-0.9%	7.1%	—
Operating income	-19.0%	-9.4%	—
Net income	-54.2%	-36.3%	—

Average margins

Over each period

	1 year	3 years	5 years	10 years
Gross margin	42.0%	42.4%	43.5%	—
Operating margin	6.4%	8.0%	12.1%	—
Net margin	0.8%	2.5%	6.5%	—

Valuation history

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021
Price to earnings	131.6	177.2	375.9	27.5	22.6
Price to sales	1.0	1.4	1.9	2.1	4.2

Dividends and splits

Per share, in the currency the company pays

Paid for 4 years. Last went ex-dividend on 26 May 2025.

	FY2025	FY2024	FY2023	FY2022
Paid in the year	0.65	0.56	1.50	2.557

Sources and methodology

Data on this tab: Our data supplier
Chart on the Overview: TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.

Asset classes

Countries / Regions

Market tools

News & insights

Bundamedik Tbk PT BMHS.JK · IDR

Search any instrument

At a glance

Income statement

Balance sheet

Cash flow

Latest quarters

Financial ratios

Growth per year

Average margins

Valuation history

Dividends and splits

Sources and methodology